Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Apnimed, Inc.Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026CHEST-led panel to showcase data from the Phase 3 SynAIRgy and LunAIRo trials, exploring potential new paradigms for advancing OSA patient management
- PROCEPT BioRoboticsPROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
- BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on October 10, 2026, under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in September 2026.
- Kaplan Fox & Kilsheimer LLPKaplan Fox & Kilsheimer LLP Notifies Hims & Hers Health, Inc. (HIMS) Investors of a Securities Class Action and a November 2, 2026 Lead Plaintiff DeadlineKaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may also...
- UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & KorsinskyA securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection
- Fair2Care: La Feria de Cantón lanza por primera vez una experiencia médica internacionalGUANGZHOU, China, 12 de octubre de 2026 -- La 140ª edición de la Feria de Cantón abrirá sus puertas el 15 de octubre ofreciendo una experiencia totalmente nueva a los asistentes. Por primera vez, la feria presenta el exclusivo Programa Fair2Care International Medical...
- GoogleApplying technology to understand and treat diseaseCompanies: Alphabet Inc.In collaboration with scientists and research partners, Google is helping to make disease more detectable, treatable, and preventable — with the goal of improving health…
- Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial ExtensionCompanies: Regeneron PharmaceuticalsPasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP
- WellGuard AssuranceWellGuard Assurance and Centrus Health Direct Partner to Expand Access to High-Performance Healthcare for Small EmployersWellGuard Assurance and Centrus Health Direct today announced an agreement designed to help small and mid-sized employers access high-quality care while helping employers and their employees manage the rising cost of healthcare. Through this...
- DeepSight Technology, Inc.DeepSight Technology Appoints Scott Huennekens to Board of DirectorsFormer Volcano and Verb Surgical CEO brings extensive experience in interventional imaging, surgical robotics, and medical technology commercialization as DeepSight advances its Physical AI platform — DeepSight Technology, Inc., a company...
- Impulse Dynamics® Presented Real-World, Late-Breaking Data Revealing Heart Failure Hospitalization Reduction and Sustained Clinical Benefits of CCM® Therapy at One YearU.S. Post-Approval Study Results Presented at Heart Failure Society of America Annual Meeting
- Alignment HealthcareAlignment Health Launches New Medicare Advantage Plan Designed for Asian American Seniors in Los Angeles and Orange CountiesNew Central Health Harmony plan offers access to more than 600 Chinese-, Korean- and Vietnamese-speaking physicians, culturally tailored benefits and leading provider partners including Astrana Health